Loading...
XTAI
1737
Market cap202mUSD
Dec 05, Last price  
31.65TWD
1D
0.00%
1Q
-2.16%
Jan 2017
8.02%
IPO
15.22%
Name

Taiyen Biotech Co Ltd

Chart & Performance

D1W1MN
XTAI:1737 chart
P/E
17.04
P/S
1.95
EPS
1.86
Div Yield, %
3.79%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
2.18%
Revenues
3.24b
-5.01%
1,980,143,0002,152,877,0002,298,251,0002,296,293,0002,408,819,0002,597,177,0002,761,204,0002,755,185,0002,757,075,0003,001,462,0002,906,615,0003,130,347,0004,095,651,0003,613,607,0003,408,811,0003,238,152,000
Net income
372m
+23.68%
209,768,000181,410,000194,067,00078,105,000125,954,000214,469,000268,930,000351,967,000353,694,000452,741,000345,503,000365,085,000393,227,000426,704,000300,386,000371,524,000
CFO
660m
+45.23%
358,023,000300,887,000246,089,000154,460,000203,212,000371,061,000383,926,000568,064,000607,866,000449,834,000330,807,000339,356,000600,076,000580,689,000454,539,000660,116,000
Dividend
Aug 20, 20241.2 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Taiyen Biotech Co., Ltd. engages in the production and sale of salt products in Taiwan and internationally. Its products portfolio includes various salt and seawater chemical products; bath salt, bath salt milk, salt soap, algae soap, and shampoo; beverage and drinking water; toothpaste, salt mouthwash, and contact lenses maintenance liquid; salt for washing vegetables, fruits, and other products; and food and food additives. The company also manufactures pharmaceuticals, including cosmetics and environmental medicines. In addition, it imports and exports daily necessities and cosmetic products. Further, the company is involved in the supply, introduction, and management consulting of industrial salt technology. Taiyen Biotech Co., Ltd. was founded in 1952 and is based in Tainan, Taiwan.
URL
https://www.tybio.com.tw/
IPO date
Nov 18, 2003
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT